PKM and lung adenocarcinoma: Since many PKM2 inhibitors are in development for the treatment of lung adenocarcinoma patients with high PKM2 expression, noninvasive methods (e.g. molecular imaging) that can predict PKM2 status and be used to monitor the effects of PKM2-targeted therapeutics are of great clinical relevance.